Adverse effects of short-term, very-low-salt diets in subjects with risk-factor clustering

American Journal of Clinical Nutrition

Volumn 65, Issue 2 SUPPL., 1997, Pages

  Egan, Brent M ^a   Stepniakowski, Konrad T ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

aldosterone; blood pressure; insulin; obesity; renin; Salt

Indexed keywords

BLOOD PRESSURE REGULATION; CONFERENCE PAPER; DISEASE ASSOCIATION; HIGH RISK POPULATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; OBESITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SODIUM RESTRICTION;

EID: 0031054406     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/65.2.671S     Document Type: Conference Paper

References (74)

1. Stamler J. Blood pressure and high blood pressure: aspects of risk. Hypertension 1991;18(suppl I):I-95-107.
2. Dahl LK. Possible role of chronic excess salt consumption in the pathogenesis of essential hypertension. Am J Cardiol 1961;8:571-5.
3. Intersalt Cooperative Research Group. Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24-hour urinary sodium and potassium excretion. Br Med J 1988;297:319-28.
4. de Wardener HE, Kaplun NM. On the assertion that a moderate restriction of sodium intake may have adverse health effects. Am J Hypertens 1993;6:810-4.
5. Longworth DL, Drayer JIM, Weber MA, Laragh JH. Divergent blood pressure responses during short-term sodium restriction in hypertension. Clin Pharmacol Ther 1980;27:544-6.
6. Weinberger MH, Miller JZ, Luft HC, Grim CE, Fineberg NS. Definitions and characteristics of sodium sensitivity and blood pressure resistance. Hspertension 1986;8(suppl II):II-127-34.
7. Sullivan JM, Ratts TH. Sodium sensitivity in human subjects. Hemodynamic and hormonal correlates. Hypertension 1988;11:717-23.
8. Law MR, Frost CD, Wald NJ. By how much does dietary salt reduction lower blood pressure? I-Analysis of observational data among populations. Br Med J 1991;302:811-24.
9. Grim CE, Miller JZ, Luft FC, Christian JC, Weinberger MH. Genetic influences on renin, aldosterone, and the renal excretion of sodium and potassium following volume expansion and contraction in normal man. Hypertension 1979;1:583-90.
10. Sharma AM, Schattenfroh S, Kribben A, Distler A. Reliability of salt-sensitivity testing in normotensive subjects. Klin Wochenschr 1989;67:632-4.
11. Overlook A, Ruppert M, Kolloch R, et al. Divergent hemodynamic and hormonal responses to varying salt intake in normotensive subjects. Hypertension 1993;22:331-8.
12. Lifton RP, Hopkins PN, Williams RR, Hollenberg NK, Williams GH, Dluhy RG. Evidence for heritability of non-modulating essential hypertension. Hypertension 1989;13:884-9.
13. Iwaoka T, Umeda T, Ohno M, Inoue J, Sato T, Kawakami I. The effect of low and high NaCl diets on oral glucose tolerance. Klin Wochenschr 1988;66:724-8.
14. Masugi F, Ogihara T, Hashizume K, Hasegawa T, Sakaguchi K, Kumahara Y. Changes in plasma lipids and uric acid with sodium loading and sodium depletion in patients with essential hypertension. J Hum Hypertens 1988;1:293-8.
15. Alderman MH, Lamport B. Moderate sodium restriction: do the benefits justify the hazards? Am J Hypertens 1990;3:499-504.
16. Egan BM, Weder AB, Petrin J, Hoffman RG. Neurohumoral and metabolic effects of short-term dietary NaCl restriction in men: relationship to salt sensitivity status. Am J Hypertens 1991;4:416-21.
17. Lind L, Lithell H, Gustafsson IB, Pollare T, Ljunghall S. Metabolic cardiovascular risk factors and sodium sensitivity in hypertensive patients. Am J Hypertens 1992;5:502-5.
18. Ruppen M, Overlack A, Kolloch R, Kraft K, Göbel B, Stumpe KO. Neurohumoral and metabolic effects of severe and moderate salt restriction in non-obese normotensive adults. J Hypertens 1993;11:743-9.
19. Egan BM, Stepniakowski K, Goodfriend TL. Renin and aldosterone are higher and the hyperinsulinemic effect of salt restriction greater in subjects with risk factor clustering. Am J Hypertens 1994;7:886-93.
20. Omvik P, Lund-Johansen P. Is sodium restriction effective treatment of borderline and mild essential hypertension? A long-term haemodynamic study at rest and during exercise. J Hypertens 1986;4:535-41.
21. Egan BM, Stepniakowski K, Nazzaro P. Insulin levels are similar in obese salt-sensitive and salt-resistant hypertensive subjects. Hypertension 1994;23(suppl I):I-1-7.
22. Egan BM, Stepniakowski K. Effects of enalapril on the hyperinsulinemic response to severe salt restriction in obese young men with mild systemic hypertension. Am J Cardiol 1993;72:53-7.
23. Weinberger MH, Stegner JE, Fineberg NS. A comparison of two tests for the assessment of blood pressure responses to sodium. Am J Hypertens 1993;6:179-84.
24. Redgrave J, Rabinowe S, Hollenberg NK, Williams GH. Correction of abnormal renal blood flow response to angiotensin II by converting enzyme inhibition in essential hypertensives. J Clin Invest 1985;75:1285-90.
25. Seely EW, Moore TJ, Rogacz S, et al. Angiotensin-mediated renin suppression is altered in non-modulating hypertension. Hypertension 1989;13:31-7.
26. Kawasaki T, Itoh K, Uezono K, et al. Investigation of high salt intake in a Nepalese population with low blood pressure. J Hum Hypertens 1993;7:131-40.
27. Kempner W. Treatment of kidney disease and hypertensive vascular disease with rice diet. Am J Med 1948;4:545-77.
28. MacGregor GA, Markandu ND, Best FE. Double-blind randomised crossover trial of moderate sodium restriction in essential hypertension. Lancet 1982;1:351-6.
29. Australian National Health and Medical Research Council Dietary Salt Study Management Committee. Fall in blood pressure with modest reduction in dietary salt intake in mild hypertension. Lancet 1989;1:399-402.
30. Mascioli S, Grimm R, Launer C, et al. Sodium chloride raises blood pressure in normotensive subjects. The study of sodium and blood pressure. Hypertension 1991;27(suppl I):I-21-6.
31. Tuck ML, Sowers J, Dornfeld L, Kledzik G, Maxwell M. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 1981;304:930-3.
32. Wassertheil-Smoller S, Oberman A, Blaufox MD, Davis B, Langford H. The trial of antihypertensive interventions and management (TAIM) study. Am J Hypertens 1992;5:37-44.
33. Page LB, Damon A, Moellering RC. Antecedents of cardiovascular disease in six Solomon Island societies. Circulation 1974;49:1132-46.
34. Oliver WJ, Cohen EL, Neel JV. Blood pressure, sodium intake, and sodium related hormones in the Yanomamo Indians, a "no-salt" culture. Circulation 1975;52:146-51.
35. McCarron DA, Weinberger MH, Weder AB, et al. Blood pressure and metabolic response to moderate sodium chloride restriction in hypertensive patients treated with isradipine. Am J Hypertens (in press).
36. Hypertension Detection and Follow-up Program Cooperative Research Group. The effect of antihypertensive treatment on mortality in the presence of resting electrocardiographic abnormalities at baseline: the HDFP experience. Circulation 1984;70:996-1003.
37. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. III: Influence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects. Circulation 1972;45:991-1004.
38. Hypertension Detection and Follow-up Program Cooperative Group. Five year findings of the hypertension detection and follow-up program. II: Mortality by race-sex and age. JAMA 1979;242:2572-7.
39. Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European Working Party on high blood pressure in the elderly trial. Lancet 1985;1:1349-54.
40. Helgeland A. Treatment of mild hypertension: a five year controlled drug trial. The Oslo Study. Am J Med 1980;68:725-31.
41. Multiple Risk Factor Intervention Trial Group. Baseline rest electrocardiographic abnormalities, antihypertensive treatment, and mortality in the multiple risk factor intervention trial. Am J Cardiol 1985;55:1-15.
42. Alderman M, Sealey J, Cohen H, Madhavan S, Laragh J. Urinary sodium excretion and myocardial infarction in hypertensive patients: a prospective cohort study. Am J Clin Nutr 1997;65(suppl):682S-6S.
43. Egan BM. Hypertension, diuretics, and coronary heart disease: a case of apples and oranges, reciprocal prejudice, and a partially-clad emperor? Am J Hypertens 1992;5:665-6.
44. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991;324:1098-104.
45. Brunner HR, Laragh JH, Baer L, et al. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972;286:441-9.
46. Dzau VJ. Vascular renin-angiotensin system and vascular protection. J Cardiovasc Pharmacol 1993;22(suppl 5):S1-9.
47. Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 1993;153:937-42.
48. Jaffa AA, Chai KX, Chao J, et al. Effects of diabetes and insulin on expression of kallikrein and renin genes in the kidney. Kidney Int 1992;41:789-95.
49. Petrasek D, Jensen G. Tuck M, Stern N. In vitro effects of insulin on aldosterone production in rat zona glomerulosa cells. Life Sci 1992;50:1781-7.
50. Chen Y-DI, Golay A, Swislocki ALM, Reaven GM. Resistance to insulin suppression of plasma free fatty acids concentrations and insulin stimulation of glucose uptake in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1987;64:17-21.
51. Cabezas M, de Bruin TWA, de Valk HW, Shoulders CC, Jansen H, Erkelens DW. Impaired fatty acid metabolism in familial combined hyperlipidemia: a mechanism associating hepatic apolipoprotein B overproduction and insulin resistance. J Clin Invest 1993;92:160-8.
52. Chambers CE, Vesell ES, Helm C, Passananti GT, Beyer KH, Pyrazinoylguanidine: antihypertensive, hypocholesterolemic, and renin effects. J Clin Pharmacol 1992;32:1128-34.
53. Stepniakowski KT, Egan BM. Additive effects of hypertension and obesity to limit venous distensibility. Am J Physiol 1995;268:R562-8.
54. Bülow J, Madsen J, Hojgaard L. Reversibility of the effects on local circulation of high lipid concentrations in blood. Scand J Clin Lab Invest 1990;50:291-6.
55. 1-adrenoceptors. Am J Physiol 1996;270:R1340-6.
56. Hollenbeck CB, Chen N, Chen YD, Reaven GM. Relationship between plasma insulin response to oral glucose and insulin-stimulated glucose utilization in normal subjects. Diabetes 1984;33:460-3.
57. Randle PJ, Garland PB, Hales CN, Newsholme. The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963;1:785-9.
58. Strömblad G, Björntorp P, Reduced hepatic insulin clearance in rats with dietary-induced obesity. Metabolism 1986;35:323-7.
59. Havel RJ, Kane JP, Balasse ET, et al. Splanchnic metabolism of free fatty acids and production of triglycerides of very low density lipoproteins in normotriglyceridemic and hypertrilgyceridemic humans. J Clin Invest 1970;49:2017-35.
60. Hall JE, Summers RL, Brands MW, Keen H, Alonso-Galicia, Resistance to metabolic actions of insulin and its role in hypertension. Am J Hypertens 1994;7:772-88.
61. Egan BM, Petrin J, Hoffmann RG, NaCl induces differential changes of regional vascular reactivity in salt-sensitive versus salt-resistant men. Am J Hypertens 1991;4:924-31.
62. Peiris AN, Mueller RA, Smith GA, Struve MF, Kissebah AH. Splanchnic insulin metabolism in obesity: influence of body fat distribution. J Clin Invest 1986;78:1648-57.
63. Talwalkar RT, Kotchen TA. Inhibition of renin by plasma linoleic acid. Am J Med Sci 1988;296:192-7.
64. Elliott ME, Goodfriend TL. Mechanism of fatty acid inhibition of aldosterone synthesis by bovine adrenal glomerulosa cells. Endocrinology 1993;132:2453-60.
65. Goodfriend TL, Egan BM, Stepniakowski K, Ball D. Relationships among plasma aldosterone, HDL cholesterol and insulin in humans. Hypertension 1995;25:30-6.
66. James DE, Burleigh KM, Storlien LH, Bennett SP, Kraegen EW. Heterogeneity of insulin action in muscle: influence of blood flow. Am J Physiol 1986;251:E422-30.
67. Laakso M, Edelman SV, Brechtel G, Baron AD. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest 1990;85:1844-52.
68. Egan BM. Neurohumoral, hemodynamic and microvascular changes as mechanisms of insulin resistance in hypertension: a provocative but partial picture. Int J Obes 1991;15:133-9.
69. Julius S, Gadbrandsson T, Jamerson K, Tariq Shahab S, Andersson O. Hypothesis: the hemodynamic link between insulin resistance and hypertension. J Hyperteas 1991;9:983-6.
70. DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ. The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J Clin invest 1975;55:845-55.
71. Baum M. Insulin stimulates volume absorption in the rabbit proximal convoluted tubule. J Clin Invest 1987;79:1104-9.
72. Egan BM. Insulin resistance and hypertension. In: Di Pette DJ, ed. Chances are: clinical probabilities in hypertension. Vol 3, Cedar Grove. NJ: Healthscan Publications, 1992:3-6.
73. Neel JV. Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"? Am J Hum Genet 1962;14:353-62.
74. Folkow B, Ely DL. Dietary sodium effects on cardiovascular and sympathetic neuroeffector functions as studied in various rat models. J Hypertens 1987;5:383-95.